Drug
MS-20
MS-20 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
3
75%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
Completed2
unknown2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (25.0%)
N/A3 (75.0%)
Trials by Status
completed250%
unknown250%
Recent Activity
0 active trials
Showing 4 of 4
completednot_applicable
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
NCT04909034
unknownnot_applicable
MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients
NCT04600154
completednot_applicable
The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals
NCT04674839
unknownphase_2
Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
NCT00707681
Clinical Trials (4)
Showing 4 of 4 trials
NCT04909034Not Applicable
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
NCT04600154Not Applicable
MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients
NCT04674839Not Applicable
The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals
NCT00707681Phase 2
Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4